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Abstract Cutaneous melanoma (CM) causes the greatest
number of skin cancer-related deaths worldwide. Predicting
CM prognosis is important to determine the need for further
investigation, counseling of patients, to guide appropriate
management (particularly the need for postoperative adjuvant
therapy), and for assignment of risk status in groups of pa-
tients entering clinical trials. Since recurrence rate is largely
independent from stages defined by morphological and mor-
phometric criteria, there is a strong need for identification of
additional robust prognostic factors to support decision-
making processes. Most data on prognostic biomarkers in
melanoma have been evaluated in tumor tissue samples by
conventional morphology and immunohistochemistry (IHC)
as well as DNA and RNA analyses. In the present review, we
critically summarize main high-quality studies investigating
IHC-based protein biomarkers of melanoma outcome accord-
ing to Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK)-derived criteria. Pathways
have been classified and conveyed in the “biologic road”
previously described by Hanahan andWeinberg. Data derived
from genomic and transcriptomic technologies have been
critically reviewed to better understand if any of investigated
proteins or gene signatures should be incorporated into clini-
cal practice or still remain a field of melanoma research.
Despite a wide body of research, no molecular prognostic
biomarker has yet been translated into clinical practice.
Conventional tissue biomarkers, such as Breslow thickness,
ulceration, mitotic rate and lymph node positivity, remain the
backbone prognostic indicators in melanoma.
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Introduction
The global incidence of melanoma is increasing, with approx-
imately 200,000 new cases and 65,000 melanoma-associated
deaths each year [1, 2]. Overall, cutaneous melanoma
(CM) accounts for only 4 % of all skin cancers; how-
ever, it causes the greatest number of skin cancer-related
deaths worldwide [3].
As for many other cancers, mortality in melanoma is main-
ly related to metastatic spread to sites distant from the primary
tumor and the prognostic parameters of the current melanoma
American Joint Committee on Cancer (AJCC) staging system
[4] represent the primary stratification criteria. Melanoma
accurate prediction of prognosis is important to determine
the need for further investigation, counseling of patients, to
guide appropriate management (particularly the need for post-
operative adjuvant therapy), and for assignment of risk status
in groups of patients entering clinical trials.
However, according to AJCC staging system, the chances
of relapse do not differ much between stage T2 and stage T3
patients; in addition also for melanoma detected at a very early
stage (≤1 mm, T1a or T1b) the risk of recurrence ranges
between 1 % and 12 % [5]. Such clinical observations suggest
that melanoma represents a heterogeneous group of diseases
with varied clinical behavior and response to therapy and there
is a strong need for identification of additional robust prog-
nostic factors to support decision making processes, since
recurrence rate is largely independent from stages defined by
morphological and morphometric criteria.
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Novel technologies for molecular profiling, such as next
generation DNA sequencing, have recently identified unique
molecular profiles and mutation patterns in melanoma cells.
At the RNA level, this has consisted of gene expression
profiling using various robust and high throughput methodol-
ogies. In certain instances, markers identified using these
platforms have been further examined and validated.
However, at present, the contribution of such sophisticated
and expensive techniques in predicting the prognosis of pa-
tients with melanoma, independently from conventional mor-
phologically based tissue biomarkers, is not entirely clarified.
In 2000, Hanahan andWeinberg [6] reported six biological
capabilities (hallmarks) acquired during the multistep devel-
opment of human tumors: (i) sustaining proliferative signal-
ing, (ii) evading growth suppressors, (iii) resisting cell death,
(iv) enabling replicative immortality, (v) inducing angiogene-
sis, and (vi) activating invasion and metastasis [7]. In the last
two decades, based on the emergence of new experimental
data, two further hallmarks have been added to this list: (vii)
reprogramming of energy metabolism and (viii) evading im-
mune destruction. Such eight hallmarks, as distinctive and
complementary capabilities that enable tumor growth and
metastatic dissemination, may represent the logical frame-
work in which organize and discuss the large amount of
information related to prognosis beyond conventional prog-
nostic biomarkers in CM patients.
To this aim, we performed an extensive “Medline” and
Cancerlit literature review (1995–2013). Various combina-
tions of search terms were used depending on the require-
ments of the database being searched. These terms included
“melanoma,” “prognosis,” “prognostic,” “prospective,” “bio-
markers,” in combination with “genomic” or “postgenomic”
or “immunohistochemical” or fluorescent in situ hybridization
(“FISH”) or comparative genomic hybridization (“CGH”) or
“molecular” or “incidence” or “management” or “recurrence”
or “distant recurrence” or “survival”, or “disease-free surviv-
al” or “trials” or “hallmarks” or “proliferative signaling” or
“Ki67” or “phosphohistone H3” or “cyclin” or “growth sup-
pressor” or “invasion” or “metastasis” or “lymphocytes” or
“microenvironment” or “cell death” or “apoptosis” or “mela-
noma-specific survival,” DNA microarray*, or RNA micro-
array*, or complementary DNA (cDNA) microarray,* or
gene-expression profil*, or gene expression profil*, or gene
expression signature*, or gene expression signature*, or gene
microarray*. Figure 1 shows the key advances in prognosis
melanoma determinants from conventional and molecular
features.
Because acral lentiginous, mucosal, and uveal melanomas
display different pathologic, molecular, and clinical features
from more common cutaneous superficial spreading and nod-
ular histological subtypes, studies describing results on spe-
cific melanoma subgroup, such as acral lentiginous, mucosal,
choroidal, or uveal melanomas, were excluded.
The quality of each eligible study was assessed for adher-
ence to Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) criteria [8–10]. According
to Gould Rothberg et al. [11], high-quality studies should
satisfy each of the following six criteria: (1) prospective or
retrospective cohort design with a clearly defined source
population and justifications for all excluded eligible cases;
(2) assay of primary cutaneous tumor specimens; (3) clear
descriptions of methods for tissue handling and IHC, includ-
ing antigen retrieval, selection, and preparation of both prima-
ry and secondary antibodies, as well as visualization tech-
niques; (4) a clear statement on the choice of positive and
negative controls; (5) statistical analysis using multivariable
proportional hazards modeling that adjusted for conventional
clinical prognostic factors; and (6) reporting of the resultant
adjusted hazard ratios (HRs) and their 95 % confidence inter-
vals (CIs).
Herein, we followed the literature review strategy devised
by Gould Rothberg [11] and Schramm andMann [12], and we
recorded additional eligible data for the subsequent
23 months.
Conventional tissue prognostic biomarkers
The clinical and histopathological characteristics that predict
prognosis in primary CM have been studied for more than
four decades. Presently, the following clinicopathologic prog-
nostic markers have been consistently identified in several
studies: age at diagnosis (with worse prognosis in older pa-
tients), male gender, growth phase (radial vs. vertical),
Breslow thickness (BT), level of invasion, presence of ulcer-
ation and its extension, presence and density of tumor-
infiltrating lymphocytes (TILs), presence of microsatellites,
presence of vascular and/or lymphatic invasion, and the mi-
totic rate (MR).
However, when included in the more recent prognostic
models [13–17], the absence or presence of regional nodal
metastasis has been shown to be a strong prognostic factor that
commonly negates all but a few of the variables associated
with the primary tumor such as BT, MR, and ulceration.
According to the aim of this review, we will focus on
conventional tissue prognostic biomarkers.
Breslow thickness
In 1970, Breslow [18] described a reproducible method of
classification, based on the measurement in millimeters of the
vertical thickness of the tumor. The BT is measured from the
granular layer or, if the lesion is ulcerated, from the bottom of
ulceration, up to the point of maximum infiltration.
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Adnexal involvement by melanoma is currently regarded
as in situ disease, while in the case of periadnexal extension of
melanoma, it is unclear from current evidence where the
measurement of tumor thickness should be made to most
accurately predict patient prognosis. It is generally agreed that
thickness measurements should not be based on periadnexal
extension, except when it is the only focus of invasion. In that
case, BT may be measured from the inner layer of the outer
root sheath epithelium or inner luminal surface of sweat
glands, to the furthest extent of infiltration into the periadnexal
dermis. The depth of extension of such foci beneath the
granular layer of the epidermis may also be measured and
reported (but not be recorded as the BT). Other problems in
interpretation may arise when the nature of dermal cells is
unclear (i.e., whether they represent melanoma or a pre-
existing naevus) and in cases of tumors with exophytic/
verruciform architecture. The thickness (measured from the
top of the granular layer) of any zone of regression may also
be recorded in the pathology report (but does not represent the
true BT).
This classification system is more reproducible and reliable
among pathologists and shows excellent correlation with mor-
tality. The prognosis tends to worsen progressively in loga-
rithmic function with increasing thickness, up to a thickness of
8 mm where it reaches a plateau, beyond which never reaches
100 % mortality [4]. In a population-based study of 548
patients, tumor thickness was the most significant prognostic
factor for survival of patients with localized CM [21]. More
recently, detailed evaluation of BT data recorded in the AJCC
melanoma staging database, has confirmed that BT correlates
with a highly significant decline in 5- and 10-year survival
rates survival. Among patients with T1 melanomas (≤1 mm
thickness), the 10-year survival was 92 %, but only 80 %,
63%, and 50%, in T2 (1.01 to 2.00mm, T3 (2.01 to 4.00mm)
and T4 (>4 mm) melanoma patients, respectively [4].
Mitotic rate
In 1953, Allen and Spitz [22] reported the poor survival of
patients who had primary melanomas with a high MR, but it
was not until nearly 50 years later that MR began to be
identified as an independent prognostic factor [23, 24]. In
2003, Azzola et al. [23] demonstrated that cellular prolifera-
tion within the primary tumor, as reflected by its MR, was a
more powerful prognostic indicator than ulceration in a 3,661-
patient, single-institution series.
In 2010, mitotic count was included in the pathological
substaging of pT1 melanoma [4]. In the multivariate analysis,
which formed the basis of these revised guidelines, mitotic
Fig. 1 Timeline of key advances in tissue prognostic biomarkers. a Allen
AC, Spitz S [22]. b Clark et al. [35]. c Breslow [18]. d Day et al. [29]. e
Morton et al. [19]. f Karjalainen et al. [72]. g Bittner et al. [87].
h Winnepenninckx et al. [90]. i Kashani-Sabet et al. [124]. j Gould
Rothberg et al. [125]. k Conway et al. [96]. l Hodis et al. [20]
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count was the second strongest prognostic factor after tumor
thickness in localized melanoma [25]. The strongest prognos-
tic impact of mitotic count was seen in the group of pT1
tumors, although it was also a significant factor for thicker
lesions. In the current staging system [4], it is recommended
that mitoses should be assessed in all primarymelanomas. The
MR should be expressed as the number of mitoses/mm2 and
rated in the invasive component of the melanoma from the
areas with increased mitotic activity (“hot spots”) and extend-
ing to adjacent fields for a total area of 1 mm2. If there are no
hot spots and mitoses are scattered randomly in the vertical
growth phase component, in this case an area of 1 mm2 around
a representative mitosis should be assessed and the result
expressed as the number of mitoses/mm2. When the invasive
component is <1 mm2 the simple presence or absence of a
mitosis can be designated as at least 1/mm2 (mitogenic) or
0/mm2 (non-mitogenic).
As underlined by Scolyer and Thompson [26] MR should
be recorded as the number of mitoses per mm2 and not per
high power field (HPF), for at least three reasons: 1) compar-
ison of MRs reported as n/HPF may not be reliable, because
the field diameter of an HPF can vary greatly between micro-
scopes; 2) there is an excellent inter-observer reproducibility
when the hot spot method has been reported in a number of
studies, whereas there is a poor inter-observer reproducibility
for MR when it was recorded per HPF; 3) MR has been
reported as an independent prognostic factor only when the
hot spot method, as recommended by the current version of
the AJCC staging manual, has been used.
Ulceration
The presence of ulceration must be microscopically evaluated
in each primary melanoma specimen and the interpretation of
melanoma ulceration is one of the most reproducible histo-
pathological features. Ulceration is characterized by: i) full-
thickness epidermal defect (including absence of stratum
corneum and basement membrane); ii) evidence of reactive
changes (fibrin deposition and neutrophils); iii) thinning, ef-
facement, or reactive hyperplasia of the surrounding epider-
mis in the absence of trauma or a recent surgical procedure. It
has been recently reported that extent of ulceration (measured
either as diameter or percentage of tumor width) provides
more accurate prognostic information than the mere presence
of ulceration [27] but the evaluation of such parameters is not
currently included in the pathological staging.
Thicker melanomas are more commonly ulcerated. In a
population-based series, the incidence of melanoma ulceration
in thin melanomas was only 6 %, while thick melanomas were
ulcerated in 63 % of cases [21]. Ulceration is a factor that
predicts disease outcome independently of tumor thickness.
The presence or absence of primary melanoma ulceration was
the third most powerful survival predictor in the analysis of the
current AJCC staging system [4]. Patients with ulcerated mela-
nomas had a twofold higher estimated risk of dying due to
melanoma compared to those with non-ulcerated tumors [4].
Interestingly, the presence of ulceration diminishes survival
rates to the same level as for the patients with non-ulcerated
melanomas of the next, larger thickness group. In the last
AJCC melanoma staging database, 5-year survival was 79 %
for T3a non-ulcerated melanomas, and was 82 % for T2b
ulcerated melanoma. T4a non-ulcerated melanoma showed a
5-year survival of 71 %, similar to that of T3b ulcerated
melanoma with a 68 % rate. T4b ulcerated melanoma were
associated with a 5-year survival of 53 % [4].
Tumor-infiltrating lymphocytes
The metastatic process involves a complex series of interac-
tions between the tumor and the host. Several data, first from
animal models and then from studies in cancer patients, sup-
port the hypothesis that the immune system can recognize and
reject tumors, suggesting that the ability of the tumor to evade
immune recognition (immune surveillance) often determines
the clinical course of the disease [28]. In melanoma tissue
specimens, it has long been recognized that lymphocytes may
be observed in intimate association with melanoma cells.
In 1981, Day et al. [29] reported a significantly better prog-
nosis in patients with a marked lymphocytic infiltrate within
primary CM than those with absent TILs. Clark et al. [30] later
classified TILs according to their distribution and intensity as
follows: (1) “brisk,” if the lymphocytes were present throughout
the substance of the vertical growth phase or were present and
infiltrating across the entire base of the vertical growth phase; (2)
“non-brisk,” if the lymphocytes were in one focus or more foci
of the vertical growth phase, either dispersed throughout or
situated focally in the periphery; and (3) “absent,” if there were
no lymphocytes or if the lymphocytes were present but did not
infiltrate the melanoma. Clark et al. [30] demonstrated that TILs
had prognostic significance only if observed in the vertical
growth phase but not in the radial growth phase.
The role of TILs as prognostic factors has been suggested
by several reports, although conflicting data have been report-
ed so far [21, 31–34]. Several reasons can be taken into
account to justify such discrepancies: (1) inclusion of predom-
inantly thin and radial growth phase melanomas vs. thick
melanomas; (2) difficulty in some cases to grade a TILs
infiltrate using the brisk and non-brisk categories; (3) studies
may be underpowered to demonstrate an independent prog-
nostic factor; and (4) scarce information regarding the immu-
nology and pathobiology of TILs.
Recently, Azimi et al. [34] reported a four-tier system for
grading TILs infiltrates based on the distribution and the
density of TILs observed in the dermal component of the
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tumor. By using this classification, TIL grade has been report-
ed as an independent predictor of survival and sentinel lymph
node (SLN) status in patients with melanoma [34]. Although
this study suggests that absence of TILs predicts SLN positiv-
ity and a poorer prognosis, melanoma progression still occurs,
in most cases, despite lymphocytic infiltration. Such observa-
tion, in turn, implies the inability of TILs to mount an effective
immune response.Whether TILs in such cases are functionally
defective, incompletely activated, or anergic is still open to
further investigation. Moreover, a better molecular characteri-
zation of TILs in PCM patients mandates further studies.
Clark's level
In 1969, Clark et al. [35], for the first time, formulated a
histopathological classification of melanoma based on the level
of invasion of the anatomical layers of the skin, demonstrating
that the level of invasion was closely related to survival. In level
I, melanoma is limited to the epidermis (in situ) and without
risk of distant metastases. In level II, superficial extension to the
papillary dermis, still guarantees an excellent prognosis.
Invasion of level III (infiltration of the papillary dermis up to
the reticular dermis) of IV (invasion of the reticular dermis) and
V (invasion of subcutaneous fat) instead provides a gradual
increase in the risk of metastasis and mortality. When
considered as a single variable, Clark level of invasion
is strongly associated with melanoma outcome. In a
population-based series, patients with level II melanoma had
98.8 % 5-year survival, which dropped to 92.5 % in patients
with level III melanoma, 76.7 % in patients with level IV
melanoma, and 75 % in patients with level V melanoma [21].
In the 2010 AJCC classification, Clark level of invasion is
no longer incorporated as a staging criterion, since whenMR is
considered in the multivariate analysis, level is not an inde-
pendent prognostic factor. Level has been replaced by MR in
the 2010 AJCC classification for subclassifying pT1
lesions as T1a or T1b, but in the text and in a table
comment of the AJCC chapter [4], Clark level IV or V
is referred to as a tertiary criterion for T1b in cases with no
ulceration and “if MR cannot be determined.” Clark level
should therefore be reported whenever it would form the basis
for upstaging T1 lesions.
Tumor growth phase
CM originates from the proliferation of melanocytes in the
basal layer of the epidermis and then expand radially at a later
time and invades deep into the dermis. The radial phase is the
not tumorigenic phase, characterized by the proliferation of
melanocytes in the epidermis and/or in the papillary dermis,
without formation of tumor nodule. The vertical growth phase
is that where the tumorigenic melanoma acquires the ability to
metastasize and is morphologically characterized by the pres-
ence of an expansive nodule larger than the intraepidermal
aggregates and/or by the presence of mitotic figures in the
invasive component.
Tumor regression
Regression is the segmental replacement of the melanoma by
fibrosis, with increased vascularity and melanophages, and a
lymphocytic infiltrate of variable density, with or without
residual epidermal component. Regression can be defined as
partial (involving less than 75 % of the lesion) or
extensive (involving 75 % or more of the lesion). This
phenomenon may be viewed into three temporal stages:
early, intermediate, and late. In most reports assessing
the prognostic significance of regression, intermediate,
and late regression have not been differentiated and the
prognostic significance of regression remains unclear.
Some studies report that it indicates a worse prognosis
(particularly in thin melanomas) [36, 37], whereas others did
not report poorer outcome [38]. Difficulties in interpreting
such studies include lack of a standardized diagnostic criteria
and poor interobserver reproducibility.
Lymphovascular invasion
Vascular invasion is identified by the histopathological dem-
onstration of melanoma cells within the lumina of blood
vessels or lymphatics, or both. It is an uncommon finding in
the excision specimens of primary CM (up to 8 %)
[39], and is generally regarded as a marker of poor
prognosis [40, 41]. IHC-detected LVI ranges from
16 % to 47 % [40, 42, 43] whereas BVI is uncommon
in primary melanoma (3–4 % incidence) [42, 43]. The pres-
ence lymphatic vessels invasion and blood vessels invasion
detected by IHC has been associated to melanoma prognosis
in many studies [40, 41, 43–47].
Microsatellites
Microsatellites are defined as microscopic and discontinuous
cutaneous and/or subcutaneous metastases>0.05 mm in di-
ameter found on pathologic examination, adjacent to a prima-
rymelanoma (separated from themain invasive component by
a distance of at least 0.3 mm). Microsatellites are cutaneous or
subcutaneous deposits of melanoma trapped within the lym-
phatics between the primary tumor and the regional lymph
node basin. Microsatellitosis defines a subgroup of patients at
higher-risk for regional and systemic recurrence.
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Melanoma histotype
The common melanoma histotypes (superficial spreading
melanoma, nodular melanoma, acral lentiginous melanoma
and lentigo maligna melanoma) are of little if any prognostic
significance, independent of tumor thickness. Their interpre-
tation is subjective and prone to interobserver variation.
Lymph node positivity
Melanoma commonly metastasizes by the lymphatic route,
and the disease status of regional lymph nodes is considered as
the most important prognostic indicator for patients with
melanoma. In order to assess the regional lymph node status,
SLN biopsy was developed as a standard procedure technique
in patients deemed to have significant risk of clinically occult
nodal metastases. The aim of this procedure is to detect
micrometastatic lymphatic disease for selective lymphadenec-
tomy. Depending on the extent of the pathology protocol used
and the BT of the population studied, SN positivity ranges
from 15 % to 33 % [48–50]. The more extensive sectioning
protocols, like the standardized EORTC MG protocol, in-
creases the detection rates of metastatic melanoma in SLN
and also reveals larger deposits.
Among patients with localized melanoma undergoing SLN
biopsy, the status of the sentinel node is the most important
prognostic factor. According to the 2010 AJCC classification,
clinically occult nodal metastases of melanoma found by
SLNB or elective lymphadenectomy are defined as
micrometastases, whereas nodal metastases found by clinical
or radiologic evaluation and confirmed pathologically are
classified as macrometastases.
Among patients with nodal metastases (Stage III), the num-
ber of metastatic nodes, clinical nodal status (macrometastases
vs. micrometastases), the sentinel node tumor burden (represent-
ed by maximum diameter of the largest tumor lesion), and
microanatomic tumor location within a sentinel node are the
most important predictors of survival [51, 52]. In patients with
nodal metastases, MR, primary ulceration, and primary thick-
ness are all independent prognostic factors at multivariate anal-
ysis. In contrast, for patients with nodal macrometastases, the
number of tumor-containing nodes and primary ulceration inde-
pendently predict survival at multivariate analysis.
IHC-based novel tissue biomarkers: independent
or redundant prognostic classifiers?
Validation issue strategy and related currently open issues
In the last two decades, several studies evaluated single bio-
markers for outcome prediction in melanoma patients. The
overall quality of the studies was generally poor if
benchmarked against the REMARK guidelines [8]. In partic-
ular, a minority of the studies stated explicitly that they
conformed to the REMARK checklist [11].
According to a recent meta-analysis, among 1,797 manu-
scripts reporting new tissue biomarkers for predicting out-
come in melanoma, only 37 cohort studies, collectively de-
scribing 87 assays on 62 distinct proteins, conformed to the
REMARK criteria by Gould Rothberg et al. [11].
In the present review, we updated data reported fromGould
Rothberg et al. [11] and summarized the results of the most
significant studies in Tables 1, 2, 3, 4, and 5. High-quality
clinical and translational studies evaluating new potential
IHC-based tissue biomarkers in melanoma, according to the
REMARK criteria, are reported. Described biomarkers have
been clustered according to the eight hallmarks described by
Hanahan and Weinberg [6, 7] (Fig. 2).
Even taking into account that these studies met the
REMARK criteria, a number of considerations should be
raised to understand whether these biomarkers are fully ready
to be transferred into clinical practice:
(i) small series : many of the studies included a limited
number of patients and this has reduced the statistical
power and widened the CIs, making extrapolation of
results in the general patient population very difficult to
implement;
(ii) heterogeneous/lack of staging information : most of the
studies did not report the TNM classification and includ-
ed patient cohort with heterogeneous clinical and patho-
logical characteristics, such as patients with node posi-
tive and negative, that cannot be considered as a single
entity neither from a clinical nor from a biological point
of view;
(iii) retrospective studies : the design of the studies was
generally based on retrospective series and limitations
due to patient selection criteria cannot be ruled out;
(iv) external/internal validation : only 2 out of 63 studies
reported an independent predictive molecular prognos-
tic assay for primary melanoma, replicating the inde-
pendent prognostic effect of molecular markers: (a) in a
data set drawn from a completely different patient pop-
ulation, (b) across different tissue platforms (tissue mi-
croarray in the initial study cohort vs. tissue sections in
the replication cohort), and (c) using different measure-
ment techniques (pathologist scoring vs. digital imaging
analysis);
(v) pre- and post-SNLB era : most prognostic models with
long-term follow-up have been developed with patients
who did not receive a SLN biopsy and these models have
been based on clinical factors and histologic findings in
the primary tumor. Thus, these results should not be
extrapolated to patients treated in the era of SLNB;
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(vi) heterogeneous follow-up strategy : in retrospective trials
the follow-up strategy has not been homogeneous for all
enrolled patients, therefore a lead time bias due to dif-
ferent follow-up timing cannot be excluded;
(vii) intratumoral heterogeneity/serial tissue sections bias :
all the reported studies measured the new biomarker in
a tissue section that might have been distant from the
original sections used to assess conventional prognostic
histopathological factors. Future studies should include
a protocol wherein these biomarkers are read on the
same or adjacent serial sections for all lesions, in order
to exclude biased results determined by tumor
heterogeneity;
(viii) tissue microarray (TMA) vs. whole tissue sections :
discrepancies are reported in results obtained in
TMA vs. whole sections [66, 67]. TMA sections
are less suitable for recording unevenly distribut-
ed markers in tumor tissues, therefore, the results
obtained by TMA studies cannot be automatically
translated into clinical practice where standard
whole sections are used; and
(ix) undemonstrated clinical utility : although several studies
demonstrated a strong correlation between a tissue bio-
marker and DFS or OS, this does not imply per se that
the marker should be used to direct patient care. A new
tissue biomarker should demonstrate clinical utility,
namely, that the use of the marker test to drive
patient management results in a favorable balance
of benefits to harm, leading to superior outcomes
compared wi th nonuse of the marker test .
Improvement in outcomemay relate toOS, DFS, quality
of life, or cost of care.
Table 2 Prognostic biomarkers: growth suppressors
Author year Biomarker Method/tissues Derivation
cohort (n)
Statistical
analysis
Covariates MVA Outcome HR (95 % CI) P
values
Berger et al. [70] AP-2α IHC/FFPE (TMA) 214° RTV MVA BT, U, CL, TILs,
Ms
MSS 2.14 (1.22–3.76) 0.0082
Berger et al. [71] HDM2 IHC/FFPE (TMA) 200° RTV UVA OS – 0.03
MSS 0.03
Karjalainen et al. [72] AP-2 IHC/FFPE (whole
sections)
273 Stages I–
II RTV
MVA BT DFS 3.12 (1.42–6.82) 0.0026
OS Not significant
Korabiowska et al. [73] Ku70 IHC/FFPE (whole
sections)
76° RTV MVA BT OS Ku 70 0.87 (0.82–0.92) <0.001
Ku80 Ku 80 0.85 (0.79–0.92) <0.001
McDermott et al. [74] nm23 IHC/FFPE (whole
sections)
145° RTV UVA Stage OS Not significant –
MVA
Pacifico et al. [75] nm23 IHC/FFPE (TMA) 120 Stages I–
III RTV
MVA Age, BT, U, CL OS Not significant –
Soltani et al. [76] MAP2 IHC/FFPE (whole
sections)
37° RTV MVA Age, G, BT DFS 0.18 0.003
Straume et al. [62] p16 IHC/FFPE (whole
sections)
167 Stages I–
IIII RTV
MVA BT, U, vascular
invasion, AS
OS 2.5 (1.5–4.2) 0.0008
DFS 2 0.007
Li et al. [77] ING4 IHC/FFPE (TMA) 101° RTV MVA Age, G, BT, U,
AS
OS 2.50 (1.09–5.74) 0.031
MSS 2.97 (1.02–8.63) 0.045
Lin et al. [78] SNF5 IHC/FFPE (TMA) 88° RTV MVA Age, G, BT, U,
AS
OS 5.145 (1.48–17.89) 0.010
MSS 4.637 (1.15–18.63) 0.031
Jonsson et al. [79] RBM3 IHC/FFPE (TMA) 215 Stages I–
III RTV
MVA Age, G, MR, CL,
BT
DFS Not significant –
OS 0.33 (0.18–0.61) 0.001
Jafarnejad et al. [80] Sox4 IHC/FFPE (TMA) 89°* RTV MVA Age, G OS 1.9 (1.078–3.362) 0.026
MSS 1.99 (1.087–3.658) 0.025
Chen et al. [81] SATB1 IHC/FFPE (whole
sections)
47 Stages I–
II RTV
MVA BT OS 9.92 (1.18–83.78) 0.03
AP-2 activator protein-2,AS Anatomic site, BT Breslow thickness,CL Clark's level,CI confidence interval,DFS disease-free survival, FFPE formalin-
fixed paraffin-embedded, G gender, HDM2 human homolog of murine double minute 2, HR hazard ratio, ING4 inhibitor of growth 4, MAP-2
microtubule-associated protein-2,MCAM melanoma cell adhesion molecule,MSS melanoma-specific survival,MVA multivariate analysis,MR mitotic
rate,Ms microsatellitosis,MSS melanoma-specific survival, nm23 nonmetastatic 23, NR not reported, OS overall survival, PKCα protein kinase C α,
RBM3 RNA-binding motif protein 3, RTV retrospective, SATB1 special AT-rich sequence-binding protein-1, SNF5 core subunit of SWI/SNF chromatin
remodeling complexes, SNL sentinel lymph node, SOX4 sry-related high-mobility group box transcription factor, TMA tissue microarray,U ulceration,
UVA univariate analysis, 214°, 200°, 76°, 145°, 37°, 101°, 88°, 89° incomplete TNM information, 89°* disease-free and overall survival in high-risk
patients: BT>1.5 mm
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For the above considerations, notwithstanding that hun-
dreds of such studies sought to assess the potential prognostic
value of IHC-detected protein biomarkers in predicting the
clinical course of melanoma patients, no biomolecular profile
correlated with outcome can be considered ready to enter
routine clinical practice.
Genetic microarray signatures: impact on prognosis
and technical shortcomings
Genomic and transcriptomic technologies make the analysis
of gene expression signatures and mutation status possible so
that tumors may be classified more accurately with respect to
diagnosis and prognosis.
In their pioneering study, Bittner et al. [87] reported,
through gene expression profiling analysis, two molecular
subtypes of metastatic melanoma with possible prognostic
significance. Since the publication of this first signature in
the late 1990s, high-throughput gene expression analysis has
revolutionized genetics over the last 13 years. Nevertheless,
scientific excitement about the attractiveness of molecular
technologies has been temperate by results that did not reach
scientific evidence of clinical benefit. Furthermore, it is not
still clear whether these expensive and complex techniques
can be applied extensively for routine use.
Recently, molecular studies reporting gene expression pro-
files in melanoma have been reviewed [88]. From more than
100 articles available in the literature, only 14 gene expression
studies that identified biomarkers associated with prognosis
fulfilled the REMARK criteria [54, 89–100, 124]. These
studies included patients with different BT, patients with
superficial spreading and nodular melanoma, with or without
SLN involvement, with different follow-up strategy and treat-
ment in the adjuvant and metastatic setting and heterogeneous
rationale of dataset construction. Samples were obtained from
different sources: primary tumor, lymph nodes, and distant
metastases. Only 4 out of 14 studies provided estimated
effects with CIs from an analysis in which the marker and
standard prognostic variables were included. Furthermore,
most of these studies did not describe the flow of patients
through the study, including the reasons for dropout. Most of
the above reported reasons may partially justify the poor
signature overlap across these 14 studies. However, other
technical reasons should be considered.
MHC II molecules were found to correlate with prognosis
in two studies [89, 93]. However, biopsies with infiltrated
metastatic lymph nodes were evaluated in both studies and
thus a small amount of residual lymphoid tissue, expressing
HLA class II molecules, could have been present.
Tumor heterogeneity, namely, non-malignant and malig-
nant melanocytes for DNA and/or RNA-based studies is a
critical issue in polymerase chain reaction and cDNA arrays in
which cells are disrupted to release genomic material from
different cell types. The scarcity of tumor samples amplifies
this confounding heterogeneity.
Furthermore, as compared to other solid tumors technical
limitations in the availability of frozen tissue from primary
CM-limited large gene expression profiling study from pa-
tients with long clinical follow-up, since it is custom to fix and
embed in paraffin for histologic diagnosis the whole primary
tumor.
Finally, there is evidence that mutation frequency varies by
several orders of magnitude across patients with a given
Table 3 Prognostic biomarkers: resisting cell death
Author year Biomarker Method/tissues Derivation cohort
(n)
Statistical
analysis
Covariates MVA
BT, MR, U, NP
Outcome HR (95 % CI) P
Values
Divito et al. [82] Bcl-2 IHC/FFPE
(TMA)
159° RTV MVA Age, gender, BT,
U, CL
MSS Bcl-2 0.64
(0.48–0.86)
0.026
Ekmekcioglu et al. [83] iNOS* IHC/FFPE
(whole sections)
132 RTV Stage III MVA Age, gender, SNL
Status, In transit
disease
MSS iNOS PC 4.63
(2.60 8.25)
<0.0001
iNOS SI 7.69
(3.76 15.74)
<0.0001
Bachmann et al. [84] TNFα IHC/FFPE
(TMA)
133 RTV Stages
I–III
MVA BT, U, Age, G,
SNL Status
MSS 2.7 (1.5–4.8) 0.001
Piras et al. [85] Survivin IHC/FFPE
(whole sections)
50 RTV Stages I–II MVA BT DFS Survivin 7.320
(1.43, 37.38)
0.017
Piras et al. [63] Survivin IHC/FFPE
(whole sections)
68 RTV Stages I–II MVA BT, CL, Stage OS Not significant –
Zhuang et al. [86] GRP78 IHC/FFPE
(whole sections)
92° RTV MVA BT, U, Age, G,
MR
OS Not significant –
DFS
Bcl-2 B-cell lymphoma 2, BT Breslow thickness, CI confidence interval, CL Clark's level, DFS disease-free survival, FFPE formalin-fixed paraffin-
embedded, G gender, HR hazard ratio, GRP78 glucose-regulated protein 78, iNOS* inducible nitric oxide synthase: number of positive cells (PC) and
staining intensity (SI),MCAM melanoma cell adhesion molecule,MSS melanoma-specific survival,MVA multivariate analysis,MR mitotic rate,MSS
melanoma-specific survival, OS overall survival, RTV retrospective, SNL sentinel lymph node, TMA tissue microarray, TNF tumor necrosis factor, U
ulceration, UVA univariate analysis, 159°, 92° incomplete TNM information
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cancer type and there is also variability among individual
patients. These issues should be considered since current
analytic methods could fail to account for mutational hetero-
geneity that affects the mutational background mutation rate
[126].
BRAF/NRAS: prognostic or predictive biomarkers?
In patients with CM, the AJCC staging criteria and currently
used conventional prognostic models define subgroups of
patients with different survival. However, within each patient
subgroup, there still remains significant variability in clinical
outcome.With the advancement of cancer genomics, it is clear
that the genetic features of melanoma are heterogeneous and
relevant to melanoma progression. Driver mutations of genes
associated with the development of tumor cells, such as genes
controlling cell division and apoptosis, invasion and metasta-
sis, growth suppressor, and immune evasion have been iden-
tified in melanoma.
There is increasing evidence that CM is a genetically
heterogeneous disease, and genetic alterations can be used to
classify primary tumors into distinct subtypes. Loss of PTEN
(25–50 %) and amplification of microphthalmia-associated
transcription factor (MITF; 10–15 %), CDK2/4 (20 %), and
Cyclin D (30 %) are frequently observed [127]. Mutation of c-
KIT occurs in 20–40 % of acral and mucosal tumors [127].
More than half of primary CM show activating mutations of
NRAS (15 %) or BRAF proto-oncogenes (50 %), which are
components of the RAS-RAF-MEK-ERK signal transduction
pathway [128]. Gain-of-function BRAFV600E mutation ac-
counts for more than 70 % of the BRAF alterations described
in melanoma, with alternative point mutations at the same
position (V600D, V600K, V600R) contributing as following:
10–30 % are V600K, while V600R mutations constitute ap-
proximately 3–7 % of all BRAF mutations.
Several studies evaluated the impact of NRAS and/or
BRAF mutations on outcome in patients with primary CM
[129]. In an attempt to correlate BRAF and NRAS mutational
status with features known to influence tumor behavior in-
cluding age, gender, Breslow depth, Clark level, MR, the
presence of ulceration and AJCC staging Ellerhorst et al.
[130] performed a microdissection of 223 primary melano-
mas. In this study, survival did not differ between Stage III
patients whose primary tumors did or did not carry mutations,
even though the mutated tumors tended to produce larger
volume nodal disease.
Edlundh-Rose et al. [131] analyzed a total of 294 melano-
ma tumors from 219 patients. Mutations in BRAF exons 11
and 15 were identified in 156 (53 %) tumors and NRAS
mutations in 86 (29 %) tumors. BRAF and NRAS mutations
did not influence the overall survival from time of diagnosis.
BRAF mutation has been tested in 197 Australian patients
with metastatic melanoma in order to identify clinicopatho-
logic variables correlated with BRAFmutation status; further-
more, a survival analysis was conducted [132]. Features of the
antecedent primary melanoma significantly associated with a
BRAFmutation were the presence of mitoses, single or occult
primary melanoma, truncal location, and age at diagnosis of
primary tumor≤50 years. BRAF mutation was found to be
prognostically relevant in metastatic melanoma but not in
primary CM. Furthermore, the presence of mutant BRAF
did not seem to have any impact on the disease-free interval
from diagnosis of first-ever melanoma to first distant
metastasis.
Recently, Si et al. [133] reported the prevalence and the
prognostic relevance of BRAF V600E in 396 Chinese pa-
tients. This retrospective study suggested that BRAF/NRAS
may be independent adverse prognostic factors in melanoma.
However, mucosal and unknown primary melanoma have
been included; furthermore, it is not clear whether these data
obtained in Chinese patients can be extrapolated in Caucasian
population.
Fig. 2 Main prognostic
biomarkers conformed to the
REMARK criteria reported in
primary cutaneous melanoma
patients and clustered according
to hallmarks of cancer (Hanahan
and Weinberg [7])
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Finally, Devitt et al. [134] reported a prospective cohort of
249 patients. When compared to WT, multivariate analysis of
melanoma-specific survival (MSS) identified NRAS muta-
tions as an adverse prognostic factor but not BRAFV600E
mutations. However, only eight events occurred for NRAS
analysis; therefore, further study is warranted with a larger
prospective cohort to fully address this issue.
A recent meta-analysis found a prognostic effect for
BRAF mutation [129]. However, in this study, patients
with limited as well as metastatic disease were included
in the analysis.
Overall, the take-home message from the above-reported
studies is that BRAF and NRAS mutations are not indepen-
dent prognostic biomarkers in patients with limited (Stages I–
III) radically resected primary CM.
Perspective
The past decades witnessed important molecular advances in
the field of melanoma research. Despite a wide body of
research, no molecular prognostic biomarker has yet been
translated into clinical practice. Several biomolecular prog-
nostic factors have been reported but a limited number has
been validated in independent datasets with sufficient follow-
up, and few studies include complete clinical and pathological
information. Accordingly, at present, no single molecular
biomarker is routinely or broadly used to guide patient care
decisions. Conventional tissue biomarkers, such as BT, ulcer-
ation, mitotic rate, and lymph node positivity, remain the
backbone prognostic indicators in melanoma.
More recently, the powerful and independent prognostic
efficacy of combined marker derived from gene expression
profiling analyses has been demonstrated. The prognostic role
of multimarker molecular assays, which partially capture mel-
anoma heterogeneity and describe signalling pathways impor-
tant in melanoma biology, has been validated in independent
dataset [124, 125, 135]. Thus, in the forthcoming years, val-
idated multimarker molecular assays will emerge to supple-
ment available clinicopathological parameters for refining
prognosis in melanoma patients.
Several issues remain open and represent a call to action for
future research:
(1) To improve the quality of clinical research and specifi-
cally the adherence to higher standards for reporting
prognostic translational biomarker studies;
(2) To identify molecular markers establishing clinical utility
according to REMARK recommendation; and
(3) To develop methods that would correct for patient- and
gene-specific mutational heterogeneity and be capable to
identifying much shorter lists of plausible biological
genes useful for clinical decision-making process.
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